Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia

Haematologica

Volumn 92, Issue 9, 2007, Pages 1282-1283

  Götze, Katharina S ^a   Hoffmann, Dieter ^a   Schätzl, Hermann M ^a   Peschel, Christian ^a   Fend, Falko ^a   Decker, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CLL; EBV; Lymphoproliferative disorder; mTOR; RAD001

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; EVEROLIMUS; FLUDARABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; VALACICLOVIR; VIRUS DNA;

AGED; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; AUTOPSY; B LYMPHOCYTE; CANCER GROWTH; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FATALITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE ORGAN FAILURE; POLYMERASE CHAIN REACTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INFECTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; PROTEIN KINASES; SIROLIMUS; VIDARABINE;

EID: 36348935087     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11155     Document Type: Article

References (10)

1. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85.
2. Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma 2005;46:11-9.
3. Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004;36 Suppl 2: 495S-9S.
4. Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 2002; 16:1101-14.
5. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208-16.
6. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-6.
7. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-63.
8. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97:4285-90.
9. Muti G, Mancini V, Ravelli E, Morra E. Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Leuk Lymphoma 2005;46:1397-407.
10. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003;63: 4472-80.